1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
69BB9D0F86AA2A4D8002586000043434B
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/launching-new-biopharma-products-competitive-markets-critical-success-factors-failure-points
18
19
2018.234.97.53
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25BMR




» Products & Services » » Product Launch » Product Launch Excellence

Launching New Biopharma Products in Competitive Markets: Critical Success Factors and Failure Points

ID: PSM-369


Features:

16 Info Graphics

34 Data Graphics

760+ Metrics

9 Narratives


Pages: 62


Published: 2020


Delivery Format: Shipped


 

License Options:
close

Single User: Authorizes use by the person who places the order or for whom the order was placed.

Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.

Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.




Buy Now

 

919-403-0251

  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • STUDY SNAPSHOT
  • KEY FINDINGS
  • VIEW TOC AND LIST OF EXHIBITS
Today's biopharmaceutical launch paradigm is forking in many directions across treatments and therapeutic areas. Many new innovations often target previously under-served patient populations, while a great portion of the industry pipeline is filled with assets targeting indications that are increasingly competitive.

Launching a new biopharma product successfully in such a complex and competitive environment requires a sound strategy that successfully leverages advantages, and a tactical execution that avoids pitfalls. Best Practices, LLC undertook this benchmarking research to help biopharma leaders avert launch risks and capitalize on key launch strengths across a number of dimensions and stakeholders.

This report
captures a wealth of new benchmarks and insights around launch success factors, value dimensions for stakeholders, effective thought leader engagement and education for market entry, risk factors, and common launch pitfalls.

Industries Profiled:
Pharmaceutical; Biopharmaceutical; Biotech; Medical Device; Manufacturing; Health Care


Companies Profiled:
Adamas Pharmaceuticals; Alkermes; Allergan; Alnylam Pharmaceuticals; AstraZeneca; Atara Biotherapeutics; BSN medical; Dicerna Pharmaceuticals; EMD Serono; F1 Oncology; Incyte; Lexicon Pharmaceuticals; Mallinckrodt; Medexus Pharmaceuticals; Novartis; PanTheryx; Inc.; Pfizer; Regeneron; Sandoz; Santhera Pharmaceuticals; Servier; Shire; Sunovion; Syros Pharmaceuticals; Takeda Pharmaceuticals; Teva Pharmaceutical Industries Ltd; UCB Pharma

Study Snapshot

Best Practices, LLC engaged 31 launch leaders from 27 companies in this research through a benchmarking survey instrument and interviews.

Key topics covered in this report include:

  • Top success factors observed from launch leaders
  • Current and future risks for launch
  • The relative value of positioning and differentiation dimensions
  • The most common failure points with leveraging efficacy and safety
  • The relative value and importance of differentiation factors with different stakeholder audiences (Physicians, Payers, Patients)
  • The effectiveness of engagement and education tactics across stakeholder audiences

Key Findings

Select key insights uncovered from this report are noted below. Detailed findings are available in the full report.

  • Investment in Sales Field Force readiness is a top launch success factor: 5th overall among all success factors, investing and initiating sales preparation early enough in the timeline is essential for producing field engagement that accelerates physician awareness and trial.
  • Ensure that the right TLs are identified for engagement, in sufficient numbers: Launch leaders identified that resources for identifying the right thought leaders are the most important among TL-based launch activities. The most critical tools for TL identification are profiling and mapping – where top performing companies balance standardized processes with planning that reflects the specific product and person.
  • Ensure patient education reflects their needs and wants: While the value of differentiation factors among physicians and payers has significant overlap, commercial executives indicated that patients prioritize quality of life, addressing unmet needs, safety, reduced side effects, and ease of use.

Table of Contents

Sr. No.
Topic
Slide No.
I.
Research Objectives & Methodologypp. 3
II.
Universe of Learningpp. 4
III.
Executive Briefpp. 5
IV.
Executive Summarypp. 6-17
V.
Positioning and Differentiation, The Top Launch Success Factorpp. 18-20
VI.
Understanding New Requirements for Efficacy Dimensions & Their Valuepp. 21-24
VII.
Understanding New Requirements for Safety Dimensions & Their Valuepp. 25-28
VIII.
Preparing Market Constituents to Successfully Enter the Market, Win Share, and Drive Growthpp. 29-36
IX.
Thought Leader Engagement & Education for Market Entrypp. 37-40
X.
Physicians: Benchmarking Differentiation Factors, Engagement Tactics, & Patient Identificationpp. 41-47
XI.
Payers: Benchmarking Differentiation Factors, Engagement Tactics, and Superior Pricingpp. 48-55
XII.
Patients: Benchmarking Differentiation Factors, Engagement, & Education Tacticspp. 56-61
XIII.
About Best Practices, LLCp. 62

    List of Charts & Exhibits

    I. Executive Summary: Factors that Drive Launch Results

    • The leading launch success factor categories
    • Framework for driving successful market entry

    II. Positioning and Differentiation, The Top Launch Success Factor: Benchmarking the Relative Value of Positioning Dimensions with Stakeholders

    • Creating the right positioning for new products
    • Ranking of effectiveness of product traits with external stakeholders across the top 3 positioning categories

    III. Understanding New Requirements for Efficacy Dimensions & Their Value

    • Extremely effective efficacy dimensions for influencing the market at launch
    • Advance points requisite for a new product relative to leading treatments in order to win physician trial and payer support in a therapeutic area with existing treatments
    • Top efficacy pitfalls that can sink positioning, derail stakeholder support, and stymie growth for a new product entering a competitive marketplace

    IV. Understanding New Requirements for Safety Dimensions & Their Value

    • Importance of various safety dimensions in encouraging physicians to try a new product that enters a competitive market
    • Effectiveness of different safety dimensions (for conditions with monotherapy and combination therapies) in order to encourage physicians to try a new product entering a competitive market
    • Top safety pitfalls that can sink positioning, derail stakeholder support, and stymie growth for a new product entering a competitive marketplace

    V. Preparing Market Constituents to Successfully Enter the Market, Win Share, and Drive Growth

    • Investment level required relative to market leader for a successful market entry in a competitive marketplace
    • Resource allocation for stakeholder engagement and education activities in the peri-launch period (late phase III through the first year of launch)
    • Importance of educating and winning support from stakeholder groups in order to successfully enter a market
    • Importance of educating and winning support from stakeholder groups in order to successfully win market share
    • Importance of educating and winning support from stakeholder groups in order to successfully grow a market
    • Estimated current and future risk levels of each of the listed market shaping pitfalls that can derail a new product coming into a crowded market
    • Estimated current and future risk levels of each of the listed internal failure points that can derail a new product coming into a crowded market

    VI. Thought Leader Engagement & Education for Market Entry

    • Effectiveness of various thought leader engagement and education strategies to create an informed and receptive marketplace at launch for a new product
    • Importance of different resources for thought leader-based market entry activities
    • Importance rating for thought leader identification and management approaches

    VII. Physicians: Benchmarking Differentiation Factors, Engagement Tactics, & Patient Identification

    • Top tier product differentiation factors for physicians at market entry
    • Second tier product differentiation factors for physicians at market entry
    • Effectiveness of early physician education activities in influencing market entry success
    • Second tier early physician education activities to influence market entry success
    • Effective methods for encouraging a physician’s initial trial with the right patient type for a new product entering a competitive marketplace
    • Estimated current and future risk levels of each of the listed physician pitfalls that can derail a new product coming into a crowded market

    VIII. Payers: Benchmarking Differentiation Factors, Engagement Tactics, and Superior Pricing

    • Top tier product differentiation factors for payers at market entry
    • Second tier product differentiation factors for payers at market entry
    • Effectiveness of early payer education and engagement activities in influencing market entry success
    • Second tier early payer education and engagement activities to influence market entry success
    • Product differentiation factors permitting superior pricing against competitors with payers
    • Minimum level of superior efficacy required to charge more than a branded competitor product in a crowded marketplace
    • Estimated current and future risk levels of each of the listed payer pitfalls that can derail a new product coming into a crowded market

    IX. Patients: Benchmarking Differentiation Factors, Engagement, & Education Tactics

    • Top tier product differentiation factors for patients at market entry
    • Second tier product differentiation factors for patients at market entry
    • Effectiveness of early patient education and engagement activities in influencing market entry success
    • Second tier early patient education and engagement activities to influence market entry success
    • Estimated current and future risk levels of each of the listed patient pitfalls that can derail a new product coming into a crowded market